论文部分内容阅读
目的:探讨瑞舒伐他汀药理分析及其抗动脉粥样硬化的临床效果。方法:在医院2015年5月到2016年1月期间诊治的颈动脉粥样硬化患者中抽取70例作研究对象并随机分组,治疗组(n=35)应用瑞舒伐他汀治疗,对照组(n=35)采取阿司匹林治疗,对比2组患者治疗前后颈动脉内膜中层厚度以及不良反应发生率。结果:治疗组治疗后的颈动脉内膜中层厚度是(0.61±0.03)mm,不良反应发生率是8.57%;对照组治疗后的颈动脉内膜中层厚度是(0.80±0.11)mm,不良反应发生率是25.71%;2组上述指标的组间对比均有统计学差异(P<0.05或P<0.01)。结论:瑞舒伐他汀的抗动脉粥样硬化的临床效果可定,可明显降低其颈动脉内膜中层厚度,并药物毒副作用较小。
Objective: To investigate the pharmacological analysis of rosuvastatin and its anti-atherosclerosis clinical effect. Methods: Seventy patients with carotid atherosclerosis diagnosed and treated in the hospital from May 2015 to January 2016 were randomly divided into two groups. The treatment group (n = 35) was treated with rosuvastatin, while the control group (n = n = 35) were taken aspirin treatment, compared two groups before and after treatment of carotid artery intima-media thickness and the incidence of adverse reactions. Results: The carotid intima-media thickness in the treatment group was (0.61 ± 0.03) mm and the incidence of adverse reactions was 8.57%. The carotid intima-media thickness in the control group was (0.80 ± 0.11) mm and the adverse reactions The incidence was 25.71%. There was significant difference between the two groups (P <0.05 or P <0.01). Conclusion: The clinical effect of rosuvastatin on atherosclerosis can be fixed, can significantly reduce the carotid intima-media thickness, and drug side effects.